Founded in 2013, Aten Porus Lifesciences operates in Health Tech industry. Initially concentrating on creating innovative formulations in the generic pharmaceutical sector, the company has evolved by ...
Funding stage:
Seed
Last funding:
09/03/2022
Investors
Employee count:
24
Last 90d
24
Last 90d
Glassdoor Rating:
Aten Porus Lifesciences: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders3
Latest Filing Date30 March 2023- Funding Events13
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Aten Porus Lifesciences
As of 31 March 2023, Aten Porus Lifesciences's equity is held by 3 shareholders, with the top three being Srinivasan Namala, Aditya Kulkarni, and Arun B Papaiah.
Srinivasan Namala holds the largest stake in Aten Porus Lifesciences at 33.3% as of 31 March 2023.
As of 31 March 2023, founders collectively hold 100.0% equity in Aten Porus Lifesciences.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links